Secondary prevention of ischemic heart disease: pharmacological treatment after myocardial infarction according to follow-up protocol

The aim of this work was to assess the quality of pharmacological treatment in patients within one year after acute myocardial infarction. We performed a prospective survey of 985 consecutive patients with acute myocardial infarction who were treated in the Clinic of Cardiology of Kaunas University...

Full description

Saved in:

Bibliographic Details
Published in:	Medicina (Kaunas, Lithuania) Vol. 43; no. 2; pp. 131 - 136
Main Authors:	Milvidaite, Irena, Luksiene, Dalia, Slapikiene, Birute, Babarskiene, Marija Rūta, Liukaitis, Valdas, Maciulaitis, Romas, Kadusevicius, Edmundas, Pilviniene, Rugile
Format:	Journal Article
Language:	English Lithuanian
Published:	Switzerland 01-01-2007
Subjects:	Adrenergic beta-Antagonists - therapeutic use Aged Angioplasty, Balloon, Coronary Angiotensin-Converting Enzyme Inhibitors - administration & dosage Angiotensin-Converting Enzyme Inhibitors - therapeutic use Calcium Channel Blockers - therapeutic use Clinical Protocols Coronary Artery Bypass Diuretics - therapeutic use Drug Therapy, Combination Female Fibrinolytic Agents - administration & dosage Fibrinolytic Agents - therapeutic use Follow-Up Studies Hospitalization Humans Hypolipidemic Agents - therapeutic use Male Middle Aged Myocardial Infarction - drug therapy Myocardial Infarction - surgery Myocardial Infarction - therapy Myocardial Ischemia - prevention & control Nitrates - therapeutic use Practice Guidelines as Topic Prospective Studies Surveys and Questionnaires Time Factors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The aim of this work was to assess the quality of pharmacological treatment in patients within one year after acute myocardial infarction. We performed a prospective survey of 985 consecutive patients with acute myocardial infarction who were treated in the Clinic of Cardiology of Kaunas University of Medicine Hospital in 2004. About half of patients were hospitalized from different regions of Lithuania. According to the follow-up protocol, an information on 514 patients and their used treatment within 13.8+/-3.2 months after myocardial infarction were collected by letter with questionnaire. Beta-adrenoblockers, angiotensin-converting enzyme inhibitors, and antithrombotic drugs were the most drug used (76%, 74%, and 76%, respectively) in patients following myocardial infarction. Most of the patients used a three-drug combination (36.8%), more rarely--two-drug (24.1%) or four-drug complex (19.8%). One drug was used only in 12.1% of cases; 7.2% of patients did not use any cardiac drugs. Beta-adrenoblocker with angiotensin-converting enzyme inhibitor was the most common (40.3%) used drug combination in patients on two drug complex. The combination of beta-adrenoblocker, angiotensin-converting enzyme inhibitor, and antithrombotics was more frequently used in patients on three drug complex. The combination of two or three cardiac drugs with statin was used in several cases (1.6-10.3%). These findings underscore that the use of beta-adrenoblockers, angiotensin-converting enzyme inhibitors, and antithrombotics was high (about 75%) in patients during the first year after myocardial infarction, and the combination of these three drugs was used more commonly. The discordance between existing guidelines for statin use after myocardial infarction and current practice was determined in patients following myocardial infarction.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1648-9144 1648-9144
DOI:	10.3390/medicina43020016